Table 3

Galantamine in schizophrenia: characteristics of included studies

Reference	Study design	Patients				Treatment				Outcome measures^†

		Diagnosis	No. of patients	Mean age (and SD), yr	Nicotine use, %	Duration, wk	Dose ChEI, mg/d	Antipsychotic agent use with ChEI	Anti-cholinergic medications^*
Bora et al41	OPrT	Schz.	5	27.6 (8.5)	20	8	16	Clozapine	Allowed	PANSS, Stroop task,^NS ACP, CPT,^NS TMT (A&B),^NS RAVLT,^NS Animal naming^NS
Allen et al73^‡	RCT	Schz.	24	?	100	4	16, 24 or 32	Not clearly reported	Not clearly reported	BPRS, BACS, CPT^§, Verbal fluency^§

ACT76= Auditory Consonant Trigrams; BACS77 = Brief Assessment of Cognition in Schizophrenia; BPRS = Brief Psychiatric Rating Scale; ChEI = cholinesterase inhibitor; CPT58 = Continuous Performance Task; NS = modest trend toward improvement not statistically significant; OPrT = open prospective trial; PANSS52 = Positive and Negative Syndrome Scale; RAVLT56 = Rey Auditory Verbal Learning Test; RCT = randomized placebo-controlled trial; Schz. = schizophrenia; TMT (A&B)56 = Trail Making Test (part A and B).
↵* Concomitant use of antipsychotic drugs or other medications considered as strongly anticholinergic, such as anticholinergic agents (e.g., biperiden, trihexyphenidyl), low-potency conventional antipsychotic drugs (e.g., chlorpromazine), clozapine and tricyclic antidepressants.
↵† Outcome measures focusing on mental state and neuropsychological assessments.
↵‡ Conference proceeding abstract.
↵§ p < 0.05